Different approaches for obtaining antibodies from human B cells

Current Drug Discovery Technologies

Volumn 11, Issue 1, 2014, Pages 41-47

  Duvall, Marcus R ^a   Fiorini, Ryan N ^a  

^a INTREXON CORPORATION   (United States)

Author keywords

Antibody engineering; Antibody libraries; Display technologies; High throughput screening; Human B cell; Human monoclonal antibodies

Indexed keywords

HUMAN MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY ENGINEERING; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC ANIMAL;

ANIMALS; ANTIBODIES; B-LYMPHOCYTES; CELL SURFACE DISPLAY TECHNIQUES; HUMANS;

EID: 84900846071     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/1570163811666140121154649     Document Type: Article

References (95)

1. Glanville J, Zhai W, Berka J, et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci USA 2009; 106(48): 20216-21.
2. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4(3): 413-5.
3. Aggarwal S. What's fueling the biotech engine-2010 to 2011. Nat Biotechnol 2011; 29(12): 1083-9.
4. Elvin JG, Couston RG, van der Walle CF. Therapeutic antibodies: Market considerations, disease targets and bioprocessing. Int J Pharm 2013; 440(1): 83-98.
5. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256(5517): 495-7.
6. Maggi E, Matucci A, Vultaggio A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011; 7(1): 55-63.
7. Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36(1): 3-10.
8. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321(6069): 522-5.
9. Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, Rabbitts TH. A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 1985; 314(6008): 268-70.
10. Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006; 58(5-6): 640-56.
11. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23(9): 1073-8.
12. Geurts AM, Cost GJ, Freyvert Y, et al. Knockout Rats via Embryo Microinjection of Zinc-Finger Nucleases. Science 2009; 325(5939): 433.
13. Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999; 231(1-2): 11-23.
14. Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994; 7(1): 13-21.
15. Lonberg N. Human antibodies from transgenic animals. Nat Biotech 2005; 23(9): 1117-25.
16. Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994; 368(6474): 856-9.
17. Beerli RR, Rader C. Mining human antibody repertoires. MAbs 2010; 2(4): 365-78.
18. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotech 2005; 23(9): 1105-16.
19. Yu X, Tsibane T, McGraw PA, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008; 455(7212): 532-6.
20. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol 2000; 74(4): 1961-72.
21. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998; 393(6686): 705-11.
22. Collarini EJ, Lee FE, Foord O, et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol 2009; 183(10): 6338-45.
23. Miller G, Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci USA 1973; 70(1): 190-4.
24. Nilsson K, Klein G, Henle W, Henle G. The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV. Int J Cancer 1971; 8(3): 443-50.
25. Lanzavecchia A, Corti D, Sallusto F. Human monoclonal antibodies by immortalization of memory B cells. Curr Opin Biotechnol 2007; 18(6): 523-8.
26. Kozbor D, Roder JC. Requirements for the establishment of hightitered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique. J Immunol 1981; 127(4): 1275-80.
27. Steinitz M, Klein G, Koskimies S, Makel O. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 1977; 269(5627): 420-2.
28. Lacoste S, Wiechec E, Dos Santos Silva AG, et al. Chromosomal rearrangements after ex vivo Epstein-Barr virus (EBV) infection of human B cells. Oncogene 2010; 29(4): 503-15.
29. Simmons CP, Bernasconi NL, Suguitan AL, Jr., et al. Prophylactic and Therapeutic Efficacy of Human Monoclonal Antibodies against H5N1 Influenza. PLoS Med 2007; 4(5): E178.
30. Traggiai E, Becker S, Subbarao K, et al. An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat Med 2004; 10(8): 871-5.
31. Macagno A, Bernasconi NL, Vanzetta F, et al. Isolation of Human Monoclonal Antibodies That Potently Neutralize Human Cytomegalovirus Infection by Targeting Different Epitopes on the gH/gL/UL128-131A Complex. J Virol 2010; 84(2): 1005-13.
32. Balla-Jhagjhoorsingh SS, Willems B, Heyndrickx L, et al. Characterization of Neutralizing Profiles in HIV-1 Infected Patients from whom the HJ16, HGN194 and HK20 mAbs were Obtained. PLoS ONE 2011; 6(10): E25488.
33. Lane HC, Shelhamer JH, Mostowski HS, Fauci AS. Human monoclonal anti-keyhole limpet hemocyanin antibody-secreting hybridoma produced from peripheral blood B lymphocytes of a keyhole limpet hemocyanin-immune individual. J Exp Med 1982; 155(1): 333-8.
34. Olsson L, Kaplan HS. Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc Natl Acad Sci USA 1980; 77(9): 5429-31.
35. Nowinski R, Berglund C, Lane J, et al. Human monoclonal antibody against Forssman antigen. Science 1980; 210(4469): 537-9.
36. Larrick JW, Truitt KE, Raubitschek AA, Senyk G, Wang JC. Characterization of human hybridomas secreting antibody to tetanus toxoid. Proc Natl Acad Sci USA 1983; 80(20): 6376-80.
37. Posner MR, Elboim H, Santos D. The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies. Hybridoma 1987; 6(6): 611-25.
38. Bron D, Feinberg MB, Teng NN, Kaplan HS. Production of human monoclonal IgG antibodies against Rhesus (D) antigen. Proc Natl Acad Sci USA 1984; 81(10): 3214-7.
39. Kozbor D, Lagarde AE, Roder JC. Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines. Proc Natl Acad Sci USA 1982; 79(21): 6651-5.
40. Krause JC, Tsibane T, Tumpey TM, et al. Human Monoclonal Antibodies to Pandemic 1957 H2N2 and Pandemic 1968 H3N2 Influenza Viruses. J Virol 2012; 86(11): 6334-40.
41. Smith G. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228(4705): 1315-7.
42. Kang AS, Barbas CF, Janda KD, Benkovic SJ, Lerner RA. Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. Proc Natl Acad Sci USA 1991; 88(10): 4363-6.
43. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 1990; 348(6301): 552-4.
44. Barbas CF, 3rd, Bjorling E, Chiodi F, Dunlop N, Cababa D, Jones TM, et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1992; 89(19): 9339-43.
45. Barbas CF, 3rd, Crowe JE, Jr., Cababa D, et al. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc Natl Acad Sci USA 1992; 89(21): 10164-8.
46. Williamson RA, Burioni R, Sanna PP, Partridge LJ, Barbas CF, Burton DR. Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc Natl Acad Sci USA 1993; 90(9): 4141-5.
47. Zebedee SL, Barbas CF, Hom YL, et al. Human combinatorial antibody libraries to hepatitis B surface antigen. Proc Natl Acad Sci USA 1992; 89(8): 3175-9.
48. Schmitz U, Versmold A, Kaufmann P, Frank HG. Phage display: A molecular tool for the generation of antibodies-A review. Placenta 2000; 21 Suppl A: S106-12.
49. Roben P, Barbas SM, Sandoval L, et al. Repertoire cloning of lupus anti-DNA autoantibodies. J Clin Invest 1996; 98(12): 2827-37.
50. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 2001; 98(22): 12659-64.
51. Cai X, Garen A. Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: Selection of specific antibodies from single-chain Fv fusion phage libraries. Proc Natl Acad Sci USA 1995; 92(14): 6537-41.
52. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, et al. Highly Conserved Protective Epitopes on Influenza B Viruses. Science 2012; 337(6100): 1343-8.
53. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotech 1997; 15(6): 553-7.
54. Boder ET, Midelfort KS, Wittrup KD. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci USA 2000; 97(20): 10701-5.
55. Van Antwerp JJ, Wittrup KD. Fine Affinity Discrimination by Yeast Surface Display and Flow Cytometry. Biotechnol Prog 2000; 16(1): 31-7.
56. Weaver-Feldhaus JM, Lou J, Coleman JR, Siegel RW, Marks JD, Feldhaus MJ. Yeast mating for combinatorial Fab library generation and surface display. FEBS Lett 2004; 564(1-2): 24-34.
57. Bowley DR, Labrijn AF, Zwick MB, Burton DR. Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage. Protein Eng Des Sel 2007; 20(2): 81-90.
58. Feldhaus MJ, Siegel RW. Yeast display of antibody fragments: A discovery and characterization platform. J Immunol Methods 2004; 290(1-2): 69-80.
59. Ho M, Nagata S, Pastan I. Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci USA 2006; 103(25): 9637-42.
60. Higuchi K, Araki T, Matsuzaki O, et al. Cell display library for gene cloning of variable regions of human antibodies to hepatitis B surface antigen. J Immunol Methods 1997; 202(2): 193-204.
61. Beerli RR, Bauer M, Buser RB, et al. Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci USA 2008; 105(38): 14336-41.
62. Beerli RR, Bauer M, Schmitz N, et al. Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol J 2009; 6: 224.
63. Smith ES, Shi S, Zauderer M. Construction of cDNA libraries in vaccinia virus. Methods Mol Biol 2004; 269: 65-76.
64. Alonso-Camino V, Sánchez-Martín D, Compte M, Álvarez-Vallina LSL. Lymphocyte Display: A Novel Antibody Selection Platform Based on T Cell Activation. PLoS ONE 2009; 4(9): E7174.
65. Zhou C, Jacobsen FW, Cai L, Chen Q, Shen WD. Development of a novel mammalian cell surface antibody display platform. MAbs 2010; 2(5): 508-18.
66. Wrammert J, Smith K, Miller J, et al. Rapid cloning of highaffinity human monoclonal antibodies against influenza virus. Nature 2008; 453(7195): 667-71.
67. Coronella JA, Telleman P, Truong TD, Ylera F, Junghans RP. Amplification of IgG VH and VL (Fab) from single human plasma cells and B cells. Nucleic Acids Res 2000; 28(20): E85.
68. Liao HX, Levesque MC, Nagel A, et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods 2009; 158(1-2): 171-9.
69. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 2008; 329(1-2): 112-24.
70. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant Autoantibody Production by Early Human B Cell Precursors. Science 2003; 301(5638): 1374-7.
71. Di Niro R, Mesin L, Raki M, et al. Rapid Generation of Rotavirus-Specific Human Monoclonal Antibodies from Small-Intestinal Mucosa. J Immunol 2010; 185(9): 5377-83.
72. Wrammert J, Koutsonanos D, Li G-M, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208(1): 181-93.
73. Poulsen TR, Meijer P-J, Jensen A, Nielsen LS, Andersen PS. Kinetic, Affinity, and Diversity Limits of Human Polyclonal Antibody Responses against Tetanus Toxoid. J Immunol 2007; 179(6): 3841-50.
74. Whittle JRR, Zhang R, Khurana S, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci USA 2011; 108(34): 14216-21.
75. Jin A, Ozawa T, Tajiri K, et al. A rapid and efficient single-cell manipulation method for screening antigen-specific antibodysecreting cells from human peripheral blood. Nat Med 2009; 15(9): 1088-92.
76. Harriman WD, Collarini EJ, Sperinde GV, et al. Antibody discovery via multiplexed single cell characterization. J Immunol Methods 2009; 341(1-2): 135-45.
77. Little M, Welschof M, Braunagel M, et al. Generation of a large complex antibody library from multiple donors. J Immunol Methods 1999; 231(1-2): 3-9.
78. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization: Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222(3): 581-97.
79. Griffiths AD, Malmqvist M, Marks JD, et al. Human anti-self antibodies with high specificity from phage display libraries. EMBO J 1993; 12(2): 725-34.
80. Sheets MD, Amersdorfer P, Finnern R, et al. Efficient construction of a large nonimmune phage antibody library: The production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci USA 1998; 95(11): 6157-62.
81. Vaughan TJ, Williams AJ, Pritchard K, et al. Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Nonimmunized Phage Display Library. Nat Biotech 1996; 14(3): 309-14.
82. Griffiths AD, Williams SC, Hartley O, et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 1994; 13(14): 3245-60.
83. Feldhaus MJ, Siegel RW, Opresko LK, et al. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotech 2003; 21(2): 163-70.
84. Blaise L, Wehnert A, Steukers MP, van den Beucken T, Hoogenboom HR, Hufton SE. Construction and diversification of yeast cell surface displayed libraries by yeast mating: Application to the affinity maturation of Fab antibody fragments. Gene 2004; 342(2): 211-8.
85. Balint RF, Larrick JW. Antibody engineering by parsimonious mutagenesis. Gene 1993; 137(1): 109-18.
86. Garrard LJ, Henner DJ. Selection of an anti-IGF-1 Fab from a Fab phage library created by mutagenesis of multiple CDR loops. Gene 1993; 128(1): 103-9.
87. Hoet RM, Cohen EH, Kent RB, et al. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining- region diversity. Nat Biotechnol 2005; 23(3): 344-8.
88. Duvall M, Bradley N, Fiorini RN. A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery. MAbs 2011; 3(2): 203-8.
89. Lynch CM, Hart BW, Grewal IS. Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies. MAbs 2009; 1(1): 2-11.
90. Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 2007; 25(5): 555-61.
91. Chapman K, Pullen N, Graham M, Ragan I. Preclinical safety testing of monoclonal antibodies: The significance of species relevance. Nat Rev Drug Discov 2007; 6(2): 120-6.
92. Overdijk MB, Verploegen S, Ortiz Buijsse A, et al. Crosstalk between Human IgG Isotypes and Murine Effector Cells. J Immunol 2012; 189(7): 3430-8.
93. Loisel S, Ohresser M, Pallardy M, et al. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 2007; 62(1): 34-42.
94. Clarke J, Leach W, Pippig S, et al. Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody. Regul Toxicol Pharmacol 2004; 40(3): 219-26.
95. Sharma A, Davis CB, Tobia LAP, et al. Comparative Pharmacodynamics of Keliximab and Clenoliximab in Transgenic Mice Bearing Human CD4. J Pharmacol Exp Ther 2000; 293(1): 33-41.